In the News

bioworld-logo

Product Briefs – SeptiCyte LAB

Immunexpress, Inc. published in the American Journal of Respiratory and Clinical Care Medicine the design and results of clinical trials validating SeptiCyte™ LAB in the discrimination of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) in the Intensive Care Unit (ICU) of hospitals.
genome web

Biocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care

Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.
Reuters-Logo1

Brief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test

Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™  platform.
genome web

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis and Immunexpress partner to develop a fully automated sepsis test, allowing for fast near-patient testing, resulting in potentially life-saving clinical information.
360DX

Biocartis, Immunexpress Partner to Develop Sepsis Test

Biocartis & Immunexpress sign partnership for a sepsis host immune response test on the Idylla™ platform.
news medical life science.

Differentiating sepsis and systemic inflammatory response syndrome using biomarkers

An interview with Dr. Richard Brandon, Chief Scientific Officer, Immunexpress, conducted by April Cashin-Garbutt, MA (Cantab).
PSBJ-logo-550x455

Immunexpress wins FDA clearance for sepsis tests that could save billions of dollars

Immunexpress has won Food and Drug Administration clearance for a diagnostics test that could save hospitals billions of dollars. The FDA cleared SeptiCyte LAB analysis that tests for sepsis, a life-threatening immune response to infection.
genetic-engineering-and-biotechnology-news

FDA Clears SeptiCyte™ LAB for Suspected Sepsis Patients

The FDA granted 510(k) clearance to Immunexpress for the use of its SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (systemic inflammatory response syndrome, or SIRS) systemic inflammation in critically ill patients on their first day of intensive care unit admission.
Fierce Biotech

FDA clears Immunexpress’ RNA-based, whole-blood sepsis Dx

Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood, returns results in a few hours.
genome web

Immunexpress Receives FDA Clearance for Direct-From-Blood Sepsis Test

Revolutionary diagnostic SeptiCyte™ LAB cleared by FDA for suspected sepsis patients.
genetic-engineering-and-biotechnology-news

Speedy Sepsis Dx via Molecular Markers

To detect sepsis quickly, says Immunexpress, track the host response, not the pathogens. By Gail Dutton.
InnovateLogoTagline2-500x383

Taking Down The Hospital’s Biggest Killer

By testing white blood cells and monitoring “expression biomarkers,” SeptiCyte – a proprietary technology of Immunexpress – aims to provide faster and more accurate diagnosis of sepsis. By Gregory Zeller.